Cabaletta Bio Ownership
| CABA Stock | USD 1.67 0.01 0.60% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 50.2 M | Current Value 49.5 M | Avarage Shares Outstanding 28.3 M | Quarterly Volatility 14.2 M |
Cabaletta | Build AI portfolio with Cabaletta Stock |
Cabaletta Stock Ownership Analysis
About 68.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.24. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cabaletta Bio recorded a loss per share of 2.54. The entity had not issued any dividends in recent years. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Cabaletta Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people. For more info on Cabaletta Bio please contact the company at 267 759 3100 or go to https://www.cabalettabio.com.Cabaletta Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cabaletta Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cabaletta Bio backward and forwards among themselves. Cabaletta Bio's institutional investor refers to the entity that pools money to purchase Cabaletta Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Integral Health Asset Management, Llc | 2025-03-31 | 850 K | Acadian Asset Management Llc | 2025-03-31 | 682.7 K | Ubs Group Ag | 2025-03-31 | 490.2 K | T. Rowe Price Associates, Inc. | 2025-03-31 | 489.3 K | Fred Alger Management, Llc | 2025-03-31 | 477.2 K | Two Sigma Advisers, Llc | 2025-03-31 | 471.5 K | Superstring Capital Management Lp | 2025-03-31 | 459 K | Nuveen Asset Management, Llc | 2024-12-31 | 434.4 K | Nuveen, Llc | 2025-03-31 | 434.4 K | T. Rowe Price Investment Management,inc. | 2025-03-31 | 4 M | Adage Capital Partners Gp Llc | 2025-03-31 | 3.6 M |
Cabaletta Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cabaletta Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cabaletta Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cabaletta Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cabaletta Bio Outstanding Bonds
Cabaletta Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cabaletta Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cabaletta bonds can be classified according to their maturity, which is the date when Cabaletta Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| CA INC 47 Corp BondUS12673PAJ49 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| HEXWIN 5375 31 OCT 26 Corp BondUS12674CAA18 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cabaletta Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cabaletta Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cabaletta Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cabaletta Bio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cabaletta Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.